Literature DB >> 33202434

Canaloplasty ab interno (AbiC) - 2-Year-Results of a Novel Minimally Invasive Glaucoma Surgery (MIGS) Technique.

Sara Kazerounian1, Michael Zimbelmann2, Martin Lörtscher3, Sufian Hommayda1, Irene Tsirkinidou1, Maya Müller4.   

Abstract

PURPOSE: The aim of this study is to evaluate the long-term efficacy of a novel minimally invasive glaucoma surgery technique (MIGS), Ab interno Canaloplasty (AbiC).
MATERIAL AND METHODS: For this retrospective cohort study, we analysed the data of 25 eyes of 23 patients with open angle glaucoma who underwent an AbiC (6 eyes) or in case of an additional cataract, a combined cataract-AbiC procedure ("phacocanaloplasty ab interno", 19 eyes), respectively. Postoperatively, we investigated the intraocular pressure (IOP) and the number of still required IOP-lowering medication, as well as surgery-related complications.
RESULTS: Overall, the mean baseline IOP of 20.24 mmHg ± 5.92 (n = 25) was reduced to 10.64 mmHg ± 2.77 (n = 25, p < 0.001), 12.55 mmHg ± 3.33 (n = 22, p < 0.001) and 13.67 mmHg ± 2.15 (n = 21, p < 0.001) at 1 day, 1 year and 2 year follow-up visit, respectively. Compared to baseline, this implies a reduction in IOP of 47.4, 37.9 and 32.5%. An average glaucoma medication usage of 1.92 ± 1.04 was registered at baseline visit and was reduced to 0,05 ± 0,23 after 2 years of follow-up. 80% of patients were off medication. In 5 eyes (20%) further antiglaucomatous eye drops or surgical treatment were administered. The only surgical complications were hyphema in 5 eyes (20%) and a localized peripheral detachment of the Descemet's membrane in one eye (4%) with no late sequelae.
CONCLUSION: AbiC performed independently or combined with cataract surgery seems to be a safe and effective MIGS-technique with good long-term regulation of IOP and low risk profile. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33202434     DOI: 10.1055/a-1250-8431

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  5 in total

1.  24-Month Efficacy of Viscodilation of Schlemm's Canal and the Distal Outflow System with iTrack Ab-Interno Canaloplasty for the Treatment of Primary Open-Angle Glaucoma.

Authors:  Mark J Gallardo
Journal:  Clin Ophthalmol       Date:  2021-04-16

2.  360° Ab-Interno Schlemm's Canal Viscodilation with OMNI Viscosurgical Systems for Open-Angle Glaucoma-Midterm Results.

Authors:  Giacomo Toneatto; Marco Zeppieri; Veronica Papa; Laura Rizzi; Carlo Salati; Andrea Gabai; Paolo Brusini
Journal:  J Clin Med       Date:  2022-01-04       Impact factor: 4.241

3.  Long-term medication reduction in controlled glaucoma with iTrack ab-interno canaloplasty as a standalone procedure and combined with cataract surgery.

Authors:  Mahmoud A Khaimi
Journal:  Ther Adv Ophthalmol       Date:  2021-09-27

4.  Canaloplasty and Trabeculotomy Combined with Phacoemulsification for Glaucoma: 12-Month Results of the GEMINI Study.

Authors:  Mark J Gallardo; Mark F Pyfer; Steven D Vold; Steven R Sarkisian; Anita Campbell; Inder Paul Singh; Brian Flowers; Kavita Dhamdhere
Journal:  Clin Ophthalmol       Date:  2022-04-21

5.  Interim Analysis of STREAMLINE® Surgical System Clinical Outcomes in Eyes with Glaucoma.

Authors:  Gabriel Lazcano-Gomez; Sumit J Garg; Elizabeth Yeu; Malik Y Kahook
Journal:  Clin Ophthalmol       Date:  2022-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.